Stemedica Cell Technologies, Inc Employee Directory
Biotechnology ResearchCalifornia, United States11-50 Employees
Stemedica Cell Technologies, Inc. is a San Diego-based clinical-stage biotechnology company focused on developing and pursuing commercialization of progenitor cell therapies and related protein therapeutics for underserved medical conditions. It operates a proprietary manufacturing platform that produces allogeneic progenitor cell products in a controlled, low-oxygen, low-tension environment within a cGMP-compliant facility. Its lead candidate, ischemia-tolerant mesenchymal stem cells (itMSCs), is in clinical development for ischemic stroke and Alzheimer's disease. The company's second program centers on ischemia-tolerant neural progenitor cells (itNSCs) for spinal cord injury, and it is pursuing multi-cell therapy approaches that combine itMSCs and itNSCs for stroke and Alzheimer's disease. A notable leadership change occurred in 2023 when Michael K. Steinhauser was appointed chief executive officer and interim chair of the board.